🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesPrediabetes reversal on GLP-1 — my results so far Page 2

Prediabetes reversal on GLP-1 — my results so far

KarenAZ_mom Wed, Mar 5, 2025 at 2:11 PM 16 replies 1,721 viewsPage 2 of 4
JessicaH_TX
Senior Member
4,123
13,456
Dec 2023
Houston, TX
Mar 5, 2025 at 9:58 PM#6
LarryQC_SD said:
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 42% to 22%.

PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

After 11 months: periods became regular for the first time in a decade, testosterone levels normalized, acne cleared significantly, and — unexpectedly — my fertility specialist is optimistic about future conception.

GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.

21 16wendy_avl, jason_paloalto, Dr.LeslieOBGYN and 18 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
Mar 6, 2025 at 1:02 AM#7
KarenAZ_mom said:
Fasting glucose improved within weeks and my HbA1c barely moved for three months, which I now understand and did not at the time.

My labs after 9 months on glycaemic control: A1C 6.2%, fasting glucose 77 mg/dL, fasting insulin 4 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 6.9% and fasting glucose was 122 mg/dL. The improvement has been dramatic and consistent.

20 15tommy_boulder, hyun_seoul, jim_asheville and 17 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Mar 6, 2025 at 4:06 AM#8
JessicaH_TX said:
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 4.6 (insulin resistant) → Current = 1.0 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

Last edited: Mar 6, 2025 at 8:06 AM
19 14FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 16 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Mar 6, 2025 at 7:10 AM#9

A narrower follow-up, since the general answer is now clear:

Did your prescriber agree with that reading, and if not what was their objection?

18 13Dr.KarenChen, Dr.NateNeph, PharmD_Rodriguez and 15 others
Reply Quote Save Share Report
KarenAZ_mom
Member
567
2,567
Aug 2024
Scottsdale, AZ
Mar 6, 2025 at 9:53 PM#10
PeptideChemSF said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 24 → 12 → 6 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

Last edited: Mar 7, 2025 at 2:53 AM
16 14HPLC_Greg, LibrarianMeg, bri_stats and 13 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register